1. Home
  2. CTRM vs QTTB Comparison

CTRM vs QTTB Comparison

Compare CTRM & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.10

Market Cap

21.2M

ML Signal

HOLD

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$6.86

Market Cap

44.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
QTTB
Founded
2016
2015
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
44.3M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
CTRM
QTTB
Price
$2.10
$6.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
54.9K
177.3K
Earning Date
01-01-0001
06-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
136.78
EPS
N/A
2.42
Revenue
N/A
$53,737,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.91
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$1.38
52 Week High
$2.67
$7.65

Technical Indicators

Market Signals
Indicator
CTRM
QTTB
Relative Strength Index (RSI) 43.04 76.03
Support Level $2.07 $3.75
Resistance Level $2.20 N/A
Average True Range (ATR) 0.11 0.60
MACD -0.01 0.24
Stochastic Oscillator 17.31 73.55

Price Performance

Historical Comparison
CTRM
QTTB

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: